Overview
Practice Essentials
Respiratory alkalosis is a disturbance in acid and base balance due to alveolar hyperventilation. Alveolar hyperventilation leads to a decreased partial pressure of arterial carbon dioxide [PaCO2]. In turn, the decrease in PaCO2 increases the ratio of bicarbonate concentration to PaCO2 and, thereby, increases the pH level; thus the descriptive term respiratory alkalosis. The decrease in PaCO2 [hypocapnia] develops when a strong respiratory stimulus causes the respiratory system to remove more carbon dioxide than is produced metabolically in the tissues. [1, 2]
Respiratory alkalosis can be acute or chronic. In acute respiratory alkalosis, the PaCO2 level is below the lower limit of normal and the serum pH is alkalemic. In chronic respiratory alkalosis, the PaCO2 level is below the lower limit of normal, but the pH level is relatively normal or near normal due to compensatory mechanisms.
Respiratory alkalosis is the most common acid-base abnormality observed in patients who are critically ill. It is associated with numerous illnesses and is a common finding in patients on mechanical ventilation. Many cardiac and pulmonary disorders can manifest with respiratory alkalosis as an early or intermediate finding. When respiratory alkalosis is present, the cause may be a minor, non–life-threatening disorder. However, more serious disease processes should also be considered in the differential diagnosis.
Signs and symptoms of respiratory alkalosis
The hyperventilation syndrome can mimic many conditions that are more serious. Symptoms may include paresthesia, circumoral numbness, chest pain or tightness, dyspnea, and tetany. [11]
Acute onset of hypocapnia can cause cerebral vasoconstriction. An acute decrease in PaCO2 reduces cerebral blood flow and can cause neurologic symptoms, including dizziness, mental confusion, syncope, and seizures. Hypoxemia need not be present for the patient to experience these symptoms. [5]
Respiratory alkalosis may impair vitamin D metabolism, which may lead to vitamin D deficiency and cause symptoms such as fibromyalgia. [14]
Workup in respiratory alkalosis
Laboratory tests
Alkalemia is documented by the presence of an increased pH level [>7.45] on arterial blood gas determinations. The presence of a decreased PaCO2 level [< 35 mm Hg] indicates a respiratory etiology of the alkalemia.
The following laboratory studies may be helpful:
Serum chemistries
Complete blood count [CBC]
Liver function test
Cultures of blood, sputum, urine, and other sites
Thyroid testing
Beta-human chorionic hormone levels
Drug screens and theophylline and salicylate levels
Imaging studies
These include the following:
Chest radiography - Should be performed to help rule out pulmonary disease as a cause of hypocapnia and respiratory alkalosis
Computerized tomography [CT] scanning of the chest - May be performed if chest radiography findings are inconclusive or a pulmonary disorder is strongly considered as a differential diagnosis
Ventilation perfusion scanning - Can be considered in patients who are unable to undergo an intravenous contrast injection associated with CT scanning to assess the patient for pulmonary embolism
Brain magnetic resonance imaging [MRI] - Can be considered if a central cause of hyperventilation and respiratory alkalosis is suggested and the initial brain CT scan findings are negative or inconclusive
Management of respiratory alkalosis
The treatment of respiratory alkalosis is primarily directed at correcting the underlying disorder. Respiratory alkalosis itself is rarely life threatening. Therefore, emergent treatment is usually not indicated unless the pH level is greater than 7.5. Because respiratory alkalosis usually occurs in response to some stimulus, treatment is usually unsuccessful unless the stimulus is controlled. If the PaCO2 is corrected rapidly in patients with chronic respiratory alkalosis, metabolic acidosis may develop due to the renal compensatory drop in serum bicarbonate.
Pathophysiology
Breathing or alveolar ventilation is the body’s method of providing adequate amounts of oxygen for metabolism while removing carbon dioxide produced in the tissues. By sensing the body’s partial pressure of arterial oxygen [PaO2] and partial pressure of arterial carbon dioxide [PaCO2], the respiratory system adjusts pulmonary ventilation so that oxygen uptake and carbon dioxide elimination at the lungs are balanced with the amount used and produced by the tissues.
The PaCO2 must be maintained at a level that ensures that hydrogen ion concentrations remain in the narrow limits required for optimal protein and enzymatic function. PaO2 is not as closely regulated as the PaCO2. Adequate hemoglobin saturation can be achieved over a wide range of PaO2 levels. The movement of oxygen from the alveoli to the vascular system is dependent on pressure gradients. On the other hand, carbon dioxide diffuses much easier through an aqueous environment.
Metabolism generates a large quantity of volatile acid [carbonic acid excreted as carbon dioxide by the lungs] and nonvolatile acid. The metabolism of fats and carbohydrates leads to the formation of a large amount of carbon dioxide, [3] which combines with water to form carbonic acid. The lungs excrete the volatile fraction through ventilation so that acid accumulation does not occur. Significant alterations in ventilation can affect the elimination of carbon dioxide and lead to a respiratory acid-base disorder.
PaCO2 is normally maintained in the range of 35-45 mm Hg. Chemoreceptors in the brain [central chemoreceptors] and in the carotid bodies [peripheral chemoreceptors] sense hydrogen concentrations and influence ventilation to adjust the PCO2 and pH. This feedback regulator is how the PaCO2 is maintained within its narrow normal range. When these receptors sense an increase in hydrogen ions, breathing is increased to “blow off” carbon dioxide and subsequently reduce the amount of hydrogen ions. Various disease processes may cause stimulation of ventilation with subsequent hyperventilation. If hyperventilation is persistent, it leads to hypocapnia.
Hyperventilation refers to an increase in alveolar ventilation that is disproportionate to the rate of metabolic carbon dioxide production, leading to a PaCO2 level below the normal range, or hypocapnia. Hyperventilation is often associated with dyspnea, but not all patients who are hyperventilating complain of shortness of breath. Conversely, patients with dyspnea need not be hyperventilating.
Acute hypocapnia causes a reduction of serum levels of potassium and phosphate secondary to increased intracellular shifts of these ions. A reduction in free serum calcium also occurs. Calcium reduction is secondary to increased binding of calcium to serum albumin due to the change in pH. Many of the symptoms present in persons with respiratory alkalosis are related to hypocalcemia. [4] Hyponatremia and hypochloremia may also be present.
Acute hyperventilation with hypocapnia causes a small, early reduction in serum bicarbonate levels resulting from cellular shift of bicarbonate. Acutely, plasma pH and bicarbonate concentration vary proportionately with the PaCO2 along a range of 15-40 mm Hg. The relationship of PaCO2 to arterial hydrogen and bicarbonate is 0.7 mmol/L per mm Hg and 0.2 mmol/L per mm Hg, respectively. [5] After 2-6 hours, renal compensation begins via a decrease in bicarbonate reabsorption. The kidneys respond more to the decreased PaCO2 rather than the increased pH. Complete kidney compensation may take several days and requires normal kidney function and intravascular volume status. [5] The expected change in serum bicarbonate concentration can be estimated as follows:
Acute - Bicarbonate [HCO3-] falls 2 mEq/L for each decrease of 10 mm Hg in the PCO2; that is, ΔHCO3 = 0.2[ΔPCO2]; maximum compensation: HCO3- = 12-20 mEq/L
Chronic - Bicarbonate [HCO3-] falls 5 mEq/L for each decrease of 10 mm Hg in the PCO2; that is, ΔHCO3 = 0.5[ΔPCO2]; maximum compensation: HCO3- = 12-20 mEq/L
Note that a plasma bicarbonate concentration of less than 12 mmol/L is unusual in pure respiratory alkalosis alone and should prompt the consideration of a metabolic acidosis as well [ie, the presence of a mixed acid-base disorder]. [4]
The expected change in pH with respiratory alkalosis can be estimated with the following equations:
Acute respiratory alkalosis: Change in pH = 0.008 X [40 – PCO2]
Chronic respiratory alkalosis: Change in pH = 0.017 X [40 – PCO2]
A study by Morel et al suggested that when respiratory alkalosis is present, caution be used in the employment of venous-arterial difference in CO2 [ΔCO2] as an indicator of the adequacy of tissue perfusion [as has been proposed for shock states]. Using healthy volunteers in whom either hypocapnia or hypercapnia was induced, the investigators found a significant increase in ΔCO2 in the hypocapnic subjects, who also had a significant decrease in skin microcirculatory blood flow. [6]
Epidemiology
Frequency
United States
The frequency of respiratory alkalosis varies depending on the etiology. The most common acid-base abnormality observed in critically ill patients is respiratory alkalosis. [5]
Mortality/Morbidity
Morbidity and mortality of patients with respiratory alkalosis depend on the nature of the underlying cause of the respiratory alkalosis and associated conditions.
An Iranian study, by Hamdi et al, found primary respiratory alkalosis to be one of the mortality risk factors during hospitalization for poisoning, with the other predictors consisting of age, intensive care unit admission, consciousness level, period of hospitalization, and severe metabolic acidosis. [7]
A study by Wu et al suggested that an association exists between respiratory alkalosis and the severity of coronavirus disease 2019 [COVID-19]. The investigators reported that after adjusting for age, gender, and the presence of comorbidities [specifically, cardiovascular disease and hypertension], the hazard ratio for the development of severe COVID-19 in patients with respiratory alkalosis was 2.445. [17]
Sex
Respiratory alkalosis is equally prevalent in males and females.
Prognosis
The prognosis of respiratory alkalosis is variable and depends on the underlying cause and the severity of the underlying illness.
Lewis et al hypothesized that respiratory alkalosis may interfere with vitamin D production, contributing to the development of fibromyalgia. The investigators suggested that, possibly by suppressing the kidneys’ ability to release phosphate into the urine, alkalotic pH disrupts endogenous 1,25-dihydroxyvitamin D formation. [8]
A study by Park et al indicated that in patients with high-risk acute heart failure, respiratory alkalosis is the most frequent acid-base imbalance. However, while acidosis was found to be a significant risk factor for mortality in acute heart failure patients, this was not true for alkalosis. [9]
A study by Raphael et al indicated that in healthy older adults, low serum bicarbonate levels can be linked to a higher mortality rate no matter whether respiratory alkalosis or metabolic acidosis is responsible for the bicarbonate reduction. Among the study’s patients [mean age 76 y], the mortality hazard ratio for those with respiratory alkalosis or metabolic acidosis, compared with controls, was 1.21 or 1.17, respectively. [10]
Patient Education
Patients with hyperventilation syndrome as the etiology of their respiratory alkalosis may particularly benefit from patient education. The underlying pathophysiology should be explained in simple terms, and patients should be instructed in breathing techniques that may be used to relieve the hyperventilation. Reassurance is key for these patients.
Brinkman JE, Sharma S. Respiratory Alkalosis. StatPearls. 2022 Jan. [QxMD MEDLINE Link]. [Full Text].
Hopkins E, Sanvictores T, Sharma S. Physiology, Acid Base Balance. StatPearls. 2022 Jan. [QxMD MEDLINE Link]. [Full Text].
Kazmaier S, Weyland A, Buhre W, et al. Effects of respiratory alkalosis and acidosis on myocardial blood flow and metabolism in patients with coronary artery disease. Anesthesiology. 1998 Oct. 89[4]:831-7. [QxMD MEDLINE Link].
Effros RM, Wesson JA. Acid-Base Balance. Mason RJ, Broaddus VC, Murray JF, Nadel JA, eds. Murray and Nadel's Textbook of Respiratory Medicine. 4th ed. Philadelphia, PA: Elsevier Saunders; 2005. Vol 1: 192-93.
DuBose TD, Jr. Acidosis and Alkalosis. Kasper DL, Braunwald E, Fauci AS, Hauser Sl, Longo DL, Jameson JL,eds. Harrison's Principles of Internal Medicine. 16th. New York, NY: McGraw-Hill; 2005. 270-1.
Morel J, Gergele L, Domine A, et al. The venous-arterial difference in CO2 should be interpreted with caution in case of respiratory alkalosis in healthy volunteers. J Clin Monit Comput. 2016 Jun 10. [QxMD MEDLINE Link].
Hamdi H, Hassanian-Moghaddam H, Hamdi A, Zahed NS. Acid-base disturbances in acute poisoning and their association with survival. J Crit Care. 2016 Oct. 35:84-9. [QxMD MEDLINE Link].
Lewis JM, Fontrier TH, Coley JL. Respiratory alkalosis may impair the production of vitamin D and lead to significant morbidity, including the fibromyalgia syndrome. Med Hypotheses. 2017 May. 102:99-101. [QxMD MEDLINE Link].
Park JJ, Choi DJ, Yoon CH, et al. The prognostic value of arterial blood gas analysis in high-risk acute heart failure patients: an analysis of the Korean Heart Failure [KorHF] registry. Eur J Heart Fail. 2015 Jun. 17 [6]:601-11. [QxMD MEDLINE Link].
Raphael KL, Murphy RA, Shlipak MG, et al. Bicarbonate Concentration, Acid-Base Status, and Mortality in the Health, Aging, and Body Composition Study. Clin J Am Soc Nephrol. 2016 Feb 5. 11 [2]:308-16. [QxMD MEDLINE Link].
Phillipson EA, Duffin J. Hypoventilation and Hyperventilation Syndromes. Mason RJ, Broaddus VC, Murray JF, Nadel JA, eds. Murray and Nadel's Textbook of Respiratory Medicine. 4th ed. Philadelphia, PA: Elsevier Saunders; 2005. Vol 2: 2069-70, 2080-84.
Goldman A. Clinical tetany by forced respiration. JAMA. 1922. 78:1193-95.
Haldane JS, Poulton EP. The effects of want of oxygen on respiration. J Physiol. 1908. 37:390-407.
Lewis JM, Fontrier TH, Coley JL. Respiratory alkalosis may impair the production of vitamin D and lead to significant morbidity, including the fibromyalgia syndrome. Med Hypotheses. 2017 May. 102:99-101. [QxMD MEDLINE Link].
Kirsch DB, Jozefowicz RF. Neurologic complications of respiratory disease. Neurol Clin. 2002 Feb. 20[1]:247-64, viii. [QxMD MEDLINE Link].
Gardner WN. The pathophysiology of hyperventilation disorders. Chest. 1996 Feb. 109[2]:516-34. [QxMD MEDLINE Link].
Wu C, Wang G, Zhang Q, et al. Association Between Respiratory Alkalosis and the Prognosis of COVID-19 Patients. Front Med [Lausanne]. 2021. 8:564635. [QxMD MEDLINE Link]. [Full Text].
Author
Ranjodh Singh Gill, MD, FACP, CCD Professor of Internal Medicine and Surgery/Endocrinology, Central Virginia VA Health Care System, Virginia Commonwealth University School of Medicine
Ranjodh Singh Gill, MD, FACP, CCD is a member of the following medical societies: American Association of Physicians of Indian Origin, American College of Physicians, Endocrine Society, International Society for Clinical Densitometry, Medical Society of Virginia, North American Sikh Medical and Dental Association, Richmond Academy of Medicine
Disclosure: Nothing to disclose.
Specialty Editor Board
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Chief Editor
Zab Mosenifar, MD, FACP, FCCP Geri and Richard Brawerman Chair in Pulmonary and Critical Care Medicine, Professor and Executive Vice Chairman, Department of Medicine, Medical Director, Women's Guild Lung Institute, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine
Zab Mosenifar, MD, FACP, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society
Disclosure: Nothing to disclose.
Additional Contributors
Ryland P Byrd, Jr, MD Professor of Medicine, Division of Pulmonary Disease and Critical Care Medicine, James H Quillen College of Medicine, East Tennessee State University
Ryland P Byrd, Jr, MD is a member of the following medical societies: American College of Chest Physicians, American Thoracic Society
Disclosure: Nothing to disclose.
Acknowledgements
Gregg T Anders, DO Medical Director, Great Plains Regional Medical Command , Brooke Army Medical Center; Clinical Associate Professor, Department of Internal Medicine, Division of Pulmonary Disease, University of Texas Health Science Center at San Antonio
Disclosure: Nothing to disclose.
Jackie A Hayes, MD, FCCP Clinical Assistant Professor of Medicine, University of Texas Health Science Center at San Antonio; Chief, Pulmonary and Critical Care Medicine, Department of Medicine, Brooke Army Medical Center
Jackie A Hayes is a member of the following medical societies: Alpha Omega Alpha, American College of Chest Physicians, American College of Physicians, and American Thoracic Society
Disclosure: Nothing to disclose.
Oleh Wasyl Hnatiuk, MD Program Director, National Capital Consortium, Pulmonary and Critical Care, Walter Reed Army Medical Center; Associate Professor, Department of Medicine, Uniformed Services University of Health Sciences
Oleh Wasyl Hnatiuk, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Thoracic Society
Disclosure: Nothing to disclose.
April Lambert-Drwiega, DO Fellow, Department of Pulmonology and Critical Care Medicine, East Tennessee State University
April Lambert-Drwiega is a member of the following medical societies: American College of Physicians, American Medical Association, American Osteopathic Association, and Southern Medical Association
Disclosure: Nothing to disclose.